The Funding Desert: Why African Healthtech Gets Left Behind — and What to Do About It

Hamza Asumah, MD, MPH, MBA

The Uncomfortable Truth About African Healthtech Funding

Let me start with a number that should disturb every African healthcare entrepreneur reading this: in the first half of 2024, African healthtech companies collectively raised $42.2 million in funding. That sounds impressive until you realize it represented just 6.5% of total tech funding across the continent, and a tiny fraction of the billions flowing to healthtech companies in North America and Europe during the same period.

Africa carries roughly 24% of the global disease burden. It has the world’s highest entrepreneurship rate, with approximately 22% of working-age Africans actively starting businesses, according to the African Development Bank. It has a $66 billion annual healthcare financing gap, as Jaza Rift Ventures Managing Partner Sewu-Steve Tawia has stated publicly. Yet the investment does not match the opportunity.

This is not simply an investor perception problem. It is a structural problem, a preparation problem, and a storytelling problem. And for founders who understand it, it is a competitive advantage — because most of your peers are not solving for it.

Why the Gap Persists: The Real Barriers

A 2025 narrative review published in Health Economics Review found that even Nigerian healthtech startups that survived the post-pandemic funding boom face a distinct “post-seed conversion problem” — they get early-stage grants, they validate a product, and then they hit a wall when trying to raise growth capital. The barriers are not just financial. They include regulatory uncertainty, market trust deficits, infrastructure mismatches, and what researchers call “systemic health-sector limitations” that capital alone cannot solve.

This is the trap: founders assume that if they can just get to a Series A, their problems are solved. The reality is that Series A investors in global health look for proof of scalable, replicable, commercially viable operations. A model that works in one Accra neighborhood or one Lagos clinic district is not yet a Series A story. Building that proof requires a fundamentally different strategic approach than most African founders are using.

The 5-Step Investor-Readiness Framework for African Healthtech Founders

Step 1: Decouple Your Story from the Donor Narrative

The most common mistake I see from African healthcare founders — whether they are building in Lagos, Nairobi, Accra, or from the diaspora — is framing their work entirely through a social impact lens. Impact matters. But investors who write $2 million to $15 million checks want commercially viable operations, not grant-dependent ones. The Transform Health Fund, backed by Africa-focused investment firm AfricInvest, explicitly seeks debt and mezzanine investments ranging from $2 million to $15 million targeting supply chain transformation and innovative care delivery. Their language is commercial, not philanthropic. Match that language.

Step 2: Build Your Evidence Stack Before You Need It

Evidence is currency. For health investors, evidence means unit economics (cost per patient served, revenue per provider, churn rate), clinical outcomes data where applicable, and documented proof of payer willingness — whether that payer is an employer, an insurer, a government agency, or the patient directly. Do not wait until you are in a funding round to build this stack. Build it from day one, even at small scale.

Step 3: Localize Your Investor Pipeline

There are active investors in African healthtech right now that most founders never approach because they do not know they exist. Villgro Africa has invested in over 40 companies through grants and equity. HealthCap Africa focuses on seed and pre-Series A checks between $250,000 and $2 million. Health54, backed by Toyota Tsusho, invests from $250,000 to $5 million across seed to Series B with strong distribution networks. These are not theoretical options — they are writing checks today.

Step 4: Structure Your Business for the Payer You Actually Have

I will cover this in detail in Blog 2, but the core principle applies here: your business model must be designed around your actual payer, not your ideal payer. If insurance penetration in your market is under 20%, your model cannot depend on insurance reimbursement cycles. Investors can spot a business built on assumptions. Build on proof.

Step 5: Use the Diaspora Capital Pathway

This is the most underutilized funding pathway in African healthcare. Africans abroad send roughly $54 billion annually to sub-Saharan Africa in remittances. Financial innovations including mobile health wallets and microinsurance schemes are creating mechanisms to channel those flows into health savings and investment vehicles. Diaspora investors who understand both the African context and global business standards represent a natural bridge capital source — and they are increasingly organized through dedicated vehicles.

“The funding desert is real. But for founders who build with commercial discipline, evidence-first, and investor fluency, the scarcity becomes a moat.”